News
OTLC
0.038
0.00%
0.000
Oncotelic Therapeutics Posts Transformational 2025 Profit Surge
TipRanks · 2d ago
Oncotelic Therapeutics GAAP EPS of $0.59
Seeking Alpha · 2d ago
Press Release: Oncotelic Therapeutics Reports FY -2-
Dow Jones · 2d ago
Press Release: Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
Dow Jones · 2d ago
ONCOTELIC THERAPEUTICS REPORTS FY 2025 RESULTS HIGHLIGHTING $249M NET INCOME AND JV PIPELINE PROGRESS
Reuters · 2d ago
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
Barchart · 3d ago
Weekly Report: what happened at OTLC last week (0406-0410)?
Weekly Report · 5d ago
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
Barchart · 04/10 07:30
NightFood’s TechForce Robotics signs joint development deal with Oncotelic Therapeutics
Reuters · 04/06 12:30
Weekly Report: what happened at OTLC last week (0330-0403)?
Weekly Report · 04/06 09:11
Oncotelic forms AI-driven robotics partnership for GMP automation
TipRanks · 04/02 14:53
Oncotelic partners with TechForce Robotics to commercialize PDAOAI-enabled GMP robotics platform
Reuters · 04/02 12:33
ONCOTELIC THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH TECHFORCE ROBOTICS TO COMMERCIALIZE PDAOAI-ENHANCED GMP ROBOTICS PLATFORM
Reuters · 04/02 12:30
Oncotelic Therapeutics Delays Annual 10-K Filing
TipRanks · 04/01 01:48
Oncotelic delays annual report filing, cites incomplete financial information
Reuters · 03/31 21:16
Oncotelic Subsidiary Showcases Deciparticle Platform at BIO-Europe
TipRanks · 03/30 17:49
Oncotelic subsidiary Sapu Nano launches Deciparticle platform at BIO-Europe Spring 2026
Reuters · 03/30 13:17
Oncotelic unit Sapu Nano presents everolimus toxicology data at SOT meeting
Reuters · 03/30 10:09
Weekly Report: what happened at OTLC last week (0323-0327)?
Weekly Report · 03/30 09:11
Oncotelic unit Sapu Nano to present Deciparticle platform at BIO-Europe Spring 2026
Reuters · 03/24 12:02
More
Webull provides a variety of real-time OTLC stock news. You can receive the latest news about Oncotelic Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.